2.78
-0.255(-8.42%)
Currency In USD
| Previous Close | 3.03 |
| Open | 3.06 |
| Day High | 3.06 |
| Day Low | 2.76 |
| 52-Week High | 4.19 |
| 52-Week Low | 0.91 |
| Volume | 1.43M |
| Average Volume | 2.6M |
| Market Cap | 249.53M |
| PE | -0.98 |
| EPS | -2.84 |
| Moving Average 50 Days | 2.54 |
| Moving Average 200 Days | 1.91 |
| Change | -0.26 |
If you invested $1000 in Editas Medicine, Inc. (EDIT) since IPO date, it would be worth $152.47 as of August 18, 2025 at a share price of $2.775. Whereas If you bought $1000 worth of Editas Medicine, Inc. (EDIT) shares 5 years ago, it would be worth $74.68 as of August 18, 2025 at a share price of $2.775.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
GlobeNewswire Inc.
Jun 12, 2025 6:01 AM GMT
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approac
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
GlobeNewswire Inc.
May 14, 2025 1:31 PM GMT
Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potent
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire Inc.
May 14, 2025 11:01 AM GMT
Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSW